Summary
The chemical structure of propafenone (P) and certain experimental findings suggest that this antiarrhythmic compound could possess beta-blocking properties. To evaluate the clinical relevance of the latter cardiovascular effects of P during exercise were studied. After oral administration of P 150 and 300 mg insolution, six healthy volunteers were subjected to graded exercise. These doses of P, which are usually effective against arrhythmias, decreased exercise-induced tachycardia, whereas the systolic blood pressure was lowered but only at rest, and the diastolic pressure was slightly raised. However, taking into account dose ratio, and the intensity and duration of the reduction in exercise tachycardia, this effect of P was only about 5|X% at its maximum compared to propranolol and similar active beta-blocking compounds. The reduction in heart rate produced by P was not correlated with the plasma level nor did it show dose dependency, in contrast to beta-blocking agents, and also in contrast to its electrophysiological effects on the PQ interval.
References
Beck OA, Witt E, Hochrein H (1975) Der Einfluß des Antiarrhythmikums Propafenon auf die intrakardiale Erregungsleitung. Klinische Untersuchungen mit Hilfe der His-Bündel-Elektrographie. Z Kardiol 64: 179–187
Blanke HI, Aschbrenner B, Karsch KR, Kreuzer H (1979) Plasmaspiegel-Wirkungs-Beziehung und Organverteilung von Propafenon. Dtsch Med Wochenschr 104: 587–591
Brode E, Sachse R, Hoffmann HD (1982) Untersuchungen zur Analytik von Propafenon mittels interner Analogstandardisierung. Arzneimittelforsch 32: 1–6
Coltart DJ, Shand DG (1970) Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br Med J 3: 731–734
Hapke HJ, Prigge E (1976) Zur Pharmakologie von 2′-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophenon (Propafenon SA 79)-hydrochlorid. Arzneimittelforsch 26: 1849–1879
Hill RC, Turner P (1968) The effects of a new beta-adrenoceptive receptor blocking drug on heart rate in man. Br J Pharmacol Chemother 32: 663–670
Hollmann M, Brode E, Hotz D, Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforsch/Drug Res 33 [5]: 763–770
Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A (1981) Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 3: 1162–1173
Lienert GA (1973) Verteilungsfreie Methoden in der Biostatistik. Anton Hain, Meisenheim am Glan, Federal Republic of Germany
McDevitt DG (1977) The assessment of β-adrenoceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425
Neugebauer G (1978) Die β-Rezeptorenblockierende Wirkung des Isochinolin-Derivates We 704 im Vergleich zu Propranolol bei gesunden Probanden. BASF Aktiengesellschaft, Unternehmensbereich Pharma/Medizinische Forschung und Entwicklung/Department Humanpharmakologie, Ludwigshafen/Rhein (FR Germany) Report VP/FMH 7811
Paietta E, Pöch G, Kukovetz WR (1977) Analyse der β-Blokker-Wirkung von Propafenon (SA 79). In: Hochrein H, Hapke HJ, Beck OA (Hrsg) Fortschritte in der Pharmakotherapie von Herzrhythmusstörungen. Fischer, Stuttgart New York
Richards DA, Wookings EP, Maconochie JG (1977) Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol 4: 15–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller-Peltzer, H., Greger, G., Neugebauer, G. et al. Beta-blocking and electrophysiological effects of propafenone in volunteers. Eur J Clin Pharmacol 25, 831–833 (1983). https://doi.org/10.1007/BF00542530
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542530